½ÃÇè°ú¸ñº° °øÁö»çÇ×

  • ½ÃÇè¾È³»
  • ½ÃÇè°ú¸ñº° °øÁö»çÇ×

2025³âµµ Á¦3ȸ Àü¹®¾à»ç ÀڰݽÃÇè °øÁö»çÇ×

- °¨¿° -

1½ÃÇè³»¿ë ±¸¼º ¹× ½ÃÇè½Ã°£ (Àü °ú¸ñ °øÅë»çÇ×)

1)½ÃÇè³»¿ëÀº °øÅ뿵¿ª°ú Àü¹®¿µ¿ªÀ¸·Î ±¸¼ºµÊ.

  • °øÅ뿵¿ª : ÀÇÇÐÅë°è ¹× ÀǤý¾àÇÐ³í¹®ºñÆò
  • Àü¹®¿µ¿ª : °¨¿°

2)½ÃÇè½Ã°£

  • ÃÑ ½ÃÇè½Ã°£ : ½ÃÇèÁغñ ¹× ¾È³», °øÁö½Ã°£ µîÀ» Æ÷ÇÔÇÏ¿© 180ºÐ(3½Ã°£).

2ÃâÁ¦À¯Çü ¹× ¹èÁ¡

1)°øÅ뿵¿ª(ÃÑ20Á¡) : °´°ü½Ä 20¹®Ç× (°¢ 1Á¡)

2)Àü¹®¿µ¿ª(ÃÑ80Á¡) : °´°ü½Ä 80¹®Ç× (°¢ 1Á¡)

  • ¾à¹°¿ä¹ýÀÇ ÀûÀý¼º °ËÅä
  • ¾à¹°¿ä¹ý °ü·Ã ¹®Á¦(drug-related problems) ÆÄ¾Ç ¹× ÇØ°á¹æ¾È Á¦½Ã
  • ȯÀÚ ¸ÂÃãÇü ¾à¹° ¼±Åà ¹× ¾à¹°¿ä¹ý °èȹ ¼ö¸³
  • ¾à¹°¿ä¹ýÀÇ Ä¡·áÈ¿°ú ¹× ¾à¹° ÀÌ»ó¹ÝÀÀ ¸ð´ÏÅ͸µ
  • ȯÀÚ º¹¾à»ó´ã ¹× ±³À°
  • Ç×»ýÁ¦ °ü¸®¿¡¼­ ¾à»çÀÇ ¿ªÇÒ µî

3ÃâÁ¦¹üÀ§

1)°øÅ뿵¿ª ÃâÁ¦¹üÀ§ : ÀǾàÅë°èÀÇ ±âº»°³³ä ¹× À̸¦ Ȱ¿ëÇÑ ³í¹®Çؼ®°ú ºñÆò, ÀÓ»óÀû¿ë µî¿¡ °üÇÑ ¹®Ç×À¸·Î ÀÌ·ç¾îÁü.

  • ±Ù°Å±â¹ÝÀÇÇÐ(Evidence-Based Medicine) ¹× ±Ù°Å±â¹ÝÀÓ»ó½Ç¹«(Evidence-Based Clinical Practice, EBCP)ÀÇ ÀÌÇØ
  • ÀǾ๮ÇåÀÇ Á¾·ù ¹× Ư¡
  • ÀÓ»óÅë°èÀÇ ±âº» °³³ä
  • ³í¹®Çؼ®°ú ºñÆò, ÀÓ»óÀû¿ë

2)Àü¹®¿µ¿ª ÃâÁ¦¹üÀ§

  • °¨¿°Ä¡·áÀÇ ¿øÄ¢
    • °¨¿°ÀÇ ÀÓ»óÁõ»ó ¹× ÁõÈÄ
    • °¨¿° ¿øÀÎ º´¿øÃ¼ÀÇ È®ÀÎ
    • Ç×»ýÁ¦ÀÇ Ç×±ÕÀÛ¿ë Æò°¡
    • °æÇèÀû Ç×»ýÁ¦ Ä¡·á¿ä¹ýÀÇ ¼±ÅÃ
    • È®Á¤Àû Ç×»ýÁ¦ Ä¡·á¿ä¹ýÀÇ ¼±ÅÃ
    • Ç×»ýÁ¦ ¾à¹°Ä¡·á Æò°¡
  • °¨¿°Áúȯ
    • ÁßÃ߽Űæ°è°¨¿°
    • Æó·Å
    • »ó±âµµ°¨¿°
    • ÀÎÇ÷翣ÀÚ
    • Äڷγª19 °¨¿°
    • ÇÇºÎ¿Í ¿¬Á¶Á÷ °¨¿°
    • °¨¿°½É³»¸·¿°
    • °áÇÙ
    • À§Àå°ü°¨¿°°ú º¹°­³»°¨¿°
    • °ñ°üÀý°¨¿°
    • ¿ä·Î°¨¿°
    • ¼º¸Å°³°¨¿°
    • Áø±Õ°¨¿°
    • ¼ö¼ú ÈÄ °¨¿° ¿¹¹æ
    • »ç¶÷¸é¿ª°áÇ̹ÙÀÌ·¯½º°¨¿° ¹× ±âȸ°¨¿°
    • ¿©ÇàÀÚ °¨¿° ¹× ÇØ¿ÜÀ¯ÀÔ °¨¿°
  • Ç×»ýÁ¦ ½ºÆ©¾îµå½Ê ÇÁ·Î±×·¥(antimicrobial stewardship program)
    • Ç×±ÕÁ¦ »ç¿ë ÁöÇ¥(¿¹: DDD, DOT, SAAR µî)
    • ±¹³» Ç×»ýÁ¦ °ü¸® Áöħ

4Âü°í¹®Çå

1)Àü °ú¸ñ °øÅë Âü°í¹®Çå

°¡)¾à¹°Ä¡·áÇÐ °ü·Ã Âü°í¹®Çå

  • DiPiro JT, Yee GC, Haines ST, Nolin TD, Ellingrod VL, Posey LM, eds. Pharmacotherapy: A Pathophysiologic Approach. 12th ed., 2023.
  • Schwinghammer TL, Koehler JM, Borchert JS, Slain D, Park SK, eds. Pharmacotherapy Casebook: A Patient-Focused Approach. 12th ed., 2023.
  • Zeind CS, Carvalho MG, Cheng JW, Zaiken K, LaPointe T, eds. Applied Therapeutics: The Clinical Use of Drugs. 12th ed., 2023.
  • Chisholm-Burns MA, Schwinghammer TL, Malone PM, Kolesar JM, Bookstaver PB, Lee KC. Pharmacotherapy Principles & Practice. 6th ed., 2022.
  • Çѱ¹ÀÓ»ó¾àÇÐȸ. ¾à¹°Ä¡·áÇÐ Á¦6°³Á¤. ½ÅÀϺϽº. 2025

³ª)°øÅ뿵¿ª(ÀÇÇÐÅë°è ¹× ÀǤý¾àÇÐ³í¹®ºñÆò) °ü·Ã Âü°í¹®Çå

  • ¾à±¹½Ç¹«ºÐ°úȸ, ¾à·áÁ¤º¸ÇÐ, ½ÅÀϺϽº, 2021³â, Section III, Á¦ 9-13Àå, 16Àå
  • ¾à±¹½Ç¹«ºÐ°úȸ, ÀÓ»ó½Ç¹«¾àÇÐ, ½ÅÀϺϽº, 2024³â, 27Àå, 29Àå
  • Guyatt G, Rennie D, Meade MO & Cook DJ. Users¡¯ Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice. 3rd ed., New York, USA: McGraw Hill Education & The JAMA Network. 2015.
  • DiCenzo R, ed. Clinical Pharmacist's Guide to Biostatistics and Literature Evaluation. 2nd ed., Lenexa, KS, USA: American College of Clinical Pharmacy. 2015.
  • Browner WS, Thomas B Newman TB, Cummings SR. Designing Clinical Research. 5th ed. Wolters Kluwer. 2022.
  • Malone PM, Witt BA, Malone MJ, Peterson DM. Drug Information: A Guide for Pharmacists, 7th ed. McGraw Hill. 2022.
  • Canadian Medical Association Journal (CMAJ) evidence based medicine (EBM) series
    • Wyer PC, et al. Tips for learning and teaching evidence-based medicine: Introduction to the series. CMAJ 2004;171:347-8.
    • Barratt A, et al. Tips for learners of evidence-based medicine: 1. Relative risk reduction, absolute risk reduction and number needed to treat. CMAJ 2004;171:353-8.
    • Montoria VM, et al. Tips for learners of evidence-based medicine: 2. Measures of precision (confidence intervals). CMAJ 2005;171:611-5.

2)Àü¹®¿µ¿ª °ü·Ã Âü°í¹®Çå

[°¨¿°Ä¡·áÀÇ ¿øÄ¢]

  • 2024 Ä«¹ÙÆä³Û ³»¼º Àå³»¼¼±Õ¸ñ °¨¿°Áõ Ç×»ýÁ¦ »ç¿ë Áöħ :
    https://www.kdca.go.kr/board/board.es?mid=a20310030000&bid=0132
  • IDSA 2024 guidance on the treatment of antimicrobial resistant Gram-negative infections :
    https://www.idsociety.org/practice-guideline/amr-guidance/

[°¨¿°Áúȯ]

  • ¿¹¹æÁ¢Á¾
    • A. ¼ºÀÎ ¿¹¹æÁ¢Á¾ ÀÏÁ¤Ç¥:
      https://nip.kdca.go.kr/irhp/infm/goVcntInfo.do?menuLv=1&menuCd=115
    • B. 2025³â ¼ºÀο¹¹æÁ¢Á¾ °³Á¤¾È(Æó·Å):
      https://www.ksid.or.kr/introduce/file/vaccine_rule_2025_02(%EC%88%98%EC%A0%95).pdf
    • C. ¡®24~¡¯25Àý±â Äڷγª19 Àӽÿ¹¹æÁ¢Á¾ Áö¿ø»ç¾÷ Áöħ:
      https://www.kdca.go.kr/board/board.es?mid=a20507020000&bid=0019&list_no=726127&act=view
  • ÁßÃ߽Űæ°è°¨¿°
    • A. (±¹³») ¼ºÀÎ ¼¼±Õ¼º ¼ö¸·¿°ÀÇ ÀÓ»óÁø·áÁöħ ±Ç°í¾È:
      http://dx.doi.org/10.3947/ic.2012.44.3.140
    • B. (¹Ì±¹) Practice guidelines for the management of bacterial meningitis:
      https://www.idsociety.org/practice-guideline/bacterial-meningitis/
  • Æó·Å
    • A. (±¹³») ¼ºÀÎ Áö¿ª»çȸȹµæ Æó·Å Ç×»ýÁ¦ »ç¿ëÁöħ:
      https://www.kdca.go.kr/board/board.es?mid=a20310030000&bid=0132&tag=&act=view&list_no=726461
    • B. (±¹³») ¼ºÀκ´¿øÈ¹µæÆó·Å Áø·á ¹× Ç×»ýÁ¦ »ç¿ëÁöħ:
      https://www.kdca.go.kr/board/board.es?mid=a20310030000&bid=0132&tag=&act=view&list_no=726465
    • C. (¹Ì±¹) ATS/IDSA guidelines for diagnosis and treatment of adults with community-acquired pneumonia:
      https://www.idsociety.org/practice-guideline/community-acquired-pneumonia-cap-in-adults/
    • D. (¹Ì±¹) ATS/IDSA 2016 clinical practice guidelines for the management of adults with hospital-acquired and ventilator-associated pneumonia:
      https://www.idsociety.org/practice-guideline/hap_vap/
  • »ó±âµµ°¨¿°
    • A. (±¹³») ¼ºÀÎ ±Þ¼º »ó±âµµ °¨¿° Ç×»ýÁ¦ »ç¿ëÁöħ:
      https://www.kdca.go.kr/board/board.es?mid=a20310030000&bid=0132&tag=&act=view&list_no=726460
    • B. (±¹³») ¼Ò¾Æ ±Þ¼º »ó±âµµ °¨¿° Ç×»ýÁ¦ »ç¿ëÁöħ:
      https://www.kdca.go.kr/board/board.es?mid=a20310030000&bid=0132&tag=&act=view&list_no=726458
    • C. (±¹³») 2014³â °³Á¤ÆÇ À¯¼Ò¾Æ ÁßÀÌ¿° Áø·áÁöħ:
      https://www.otologicalsociety.or.kr/member/file/2014_01.pdf
  • ÀÎÇ÷翣ÀÚ
    • A. (±¹³») 2025-2026Àý±â ÀÎÇ÷翣ÀÚ °ü¸® Áöħ(PART II. °¢·Ð):
      https://www.kdca.go.kr/board/board.es?mid=a20604000000&bid=0019&tag=&act=view&list_no=728747
    • B. (¹Ì±¹) Clinical practice guidelines for the diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenza: 2018 update by IDSA:
      https://www.idsociety.org/practice-guideline/influenza/
  • Äڷγª19 °¨¿°
    • A. (±¹³») Äڷγª19 Ä¡·áÁ¦ »ç¿ë ¾È³»¼­(13-2ÆÇ) °³Á¤:
      https://www.kdca.go.kr/board/boardApi.es?mid=a20507050000&bid=0080&api_code=20220214
    • B. (¹Ì±¹) IDSA guidelines on the treatment and management of patients with COVID-19:
      https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/
  • ÇÇºÎ¿Í ¿¬Á¶Á÷ °¨¿°
    • A. (±¹³») ÇǺΠ¿¬Á¶Á÷ °¨¿° Ç×»ýÁ¦ »ç¿ëÁöħ:
      https://www.kdca.go.kr/board/board.es?mid=a20310030000&bid=0132&tag=&act=view&list_no=726462
    • B. (¹Ì±¹) IWGDF/IDSA guidelines on the diagnosis and treatment of diabetes-related foot infections:
      https://www.idsociety.org/practice-guideline/diabetic-foot-infections/
  • °¨¿°½É³»¸·¿°
    • A. (±¹³») ½ÉÇ÷°ü°è °¨¿° Áø·áÁöħ ±Ç°í¾È:
      https://doi.org/10.3947/ic.2011.43.2.129
    • B. (¹Ì±¹) Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications:
      https://www.idsociety.org/practice-guideline/endocarditis-management/
  • °áÇÙ
    • A. °áÇÙ Áø·áÁöħ(5ÆÇ) (2024):
      https://www.kdca.go.kr/board/board.es?mid=a20507020000&bid=0019&tag=&act=view&list_no=724490
  • À§Àå°ü°¨¿°°ú º¹°­³»°¨¿°
    • A. (±¹³») ¼ÒÈ­±â°è °¨¿° Áø·áÁöħ ±Ç°í¾È:
      https://doi.org/10.3947/ic.2010.42.6.323
    • B. (±¹³») ¼ºÀÎ º¹°­ ³» °¨¿° Ç×»ýÁ¦ »ç¿ëÁöħ:
      https://doi.org/10.3947/ic.2022.0156
    • C. (±¹³») ±Þ¼ºÀ§Àå°ü°è °¨¿° Ç×»ýÁ¦ »ç¿ëÁöħ:
      https://www.kdca.go.kr/board/board.es?mid=a20310030000&bid=0132&tag=&act=view&list_no=726464
    • D. (±¹³») 2022 ´ëÇѰ£ÇÐȸ ¸¸¼ºBÇü°£¿° Áø·á °¡À̵å¶óÀÎ:
      https://www.kasl.org/bbs/?number=5349&mode=view&code=guide&keyfield=&keyword=&category=A&gubun=&orderfield=
    • E. (±¹³») 2025 ´ëÇѰ£ÇÐȸ CÇü°£¿° Áø·á °¡À̵å¶óÀÎ:
      https://www.kasl.org/bbs/?number=6192&mode=view&code=guide&keyfield=&keyword=&category=B&gubun=&orderfield=
    • F. (¹Ì±¹) Clinical practice guidelines for the management of Clostridioides difficile infection in adults: 2021 update by SHEA/IDSA:
      https://www.idsociety.org/practice-guideline/clostridioides-difficile-2021-focused-update/
    • G. (¹Ì±¹) Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by SHEA/IDSA:
      https://www.idsociety.org/practice-guideline/clostridium-difficile/
    • H. (¹Ì±¹) IDSA 2017 clinical practice guidelines for the diagnosis and management of infectious diarrhea:
      https://www.idsociety.org/practice-guideline/infectious-diarrhea/
  • °ñ°üÀý°¨¿°
    • A. (±¹³») ±¹³» °ñ°üÀý°¨¿° Ç×±Õ¿ä¹ý ±Ç°í¾È:
      https://doi.org/10.3947/ic.2014.46.2.125
    • B. (¹Ì±¹) Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America:
      https://academic.oup.com/cid/article/56/1/e1/415705?login=false
    • C. (¹Ì±¹) IDSA 2015 clinical practice guidelines for the diagnosis and treatment of native vertebral osteomyelitis in adults:
      https://www.idsociety.org/practice-guideline/vertebral-osteomyelitis/
  • ¿ä·Î°¨¿°
    • A. (±¹³») ¿ä·Î°¨¿° Ç×»ýÁ¦ »ç¿ëÁöħ:
      https://www.kdca.go.kr/board/board.es?mid=a20310030000&bid=0132&tag=&act=view&list_no=726463
  • ¼º¸Å°³°¨¿°
    • A. (±¹³») ¼º¸Å°³°¨¿° Áø·áÁöħ(2023):
      https://www.uti.or.kr/include/pdf/KOREAN_STI_GUIDELINES_2023.pdf
  • Áø±Õ°¨¿°
    • A. (¹Ì±¹) Clinical practice guideline for the management of candidiasis: 2016 update by IDSA:
      https://www.idsociety.org/practice-guideline/candidiasis/
    • B. (¹Ì±¹) Clinical practice guideline for the diagnosis and management of aspergillosis: 2016 update by IDSA:
      https://www.idsociety.org/practice-guideline/aspergillosis/
  • ¼ö¼ú ÈÄ °¨¿° ¿¹¹æ
    • A. (±¹³») 2025³â ¼ö¼úÀÇ ¿¹¹æÀû Ç×»ýÁ¦ »ç¿ë ÀûÁ¤¼º Æò°¡ ¿ä¾ç±â°ü ¼³¸íȸ Ã¥ÀÚ:
      https://www.hira.or.kr/bbsDummy.do?pgmid=HIRAA020002000100&brdScnBltNo=4&brdBltNo=11363&pageIndex=1&pageIndex2=1
    • B. (¹Ì±¹) Clinical practice guidelines for antimicrobial prophylaxis in surgery:
      https://www.ashp.org/surgical-guidelines
  • »ç¶÷¸é¿ª°áÇ̹ÙÀÌ·¯½º°¨¿° ¹× ±âȸ°¨¿°
    • A. (±¹³») HIV °¨¿°ÀÇ Áø´Ü°ú Ä¡·á:
      https://doi.org/10.3947/ic.2021.0305
    • B. (±¹³») HIV °¨¿°ÀÎÀÇ ±âȸ°¨¿°Áõ Ä¡·á¿Í ¿¹¹æ:
      https://doi.org/10.3947/ic.2016.48.1.54
    • C. (±¹³») ±¹³» HIV ³ëÃâ Àü ¿¹¹æ¿ä¹ý ±Ç°í¾È:
      https://www.icjournal.org/src/sm/ic-49-243-s001.pdf
    • D. (±¹³») HIV °¨¿°ÀÎ Áø·á¸¦ À§ÇÑ ÀÇ·á±â°ü ±æ¶óÀâÀÌ:
      https://www.kdca.go.kr/board/board.es?mid=a20507020000&bid=0019&list_no=726253&act=view
    • E. (¹Ì±¹) Guidelines for the use of antiretroviral agents in adults and adolescents with HIV:
      https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/whats-new
    • F. (¹Ì±¹) Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/whats-new
  • ¿©ÇàÀÚ °¨¿° ¹× ÇØ¿ÜÀ¯ÀÔ °¨¿°
    • A. (±¹³») ¸»¶ó¸®¾Æ Áø·á°¡À̵å(Á¦2ÆÇ):
      https://www.kdca.go.kr/board/board.es?mid=a20501000000&bid=0019&tag=&act=view&list_no=722986
    • B. (±¹³») ÀÇ·áÀÎÀ» À§ÇÑ ¸»¶ó¸®¾Æ ¿¹¹æ ¹× °ü¸® ¾È³»¼­:
      https://www.kdca.go.kr/board/board.es?mid=a20507020000&bid=0019&list_no=725685&act=view

[Ç×»ýÁ¦ ½ºÆ©¾îµå½Ê ÇÁ·Î±×·¥(antimicrobial stewardship program)]

  • (±¹³») Ç×»ýÁ¦ »ç¿ë°ü¸® ÇÁ·Î±×·¥ ÅëÇÕ ¿î¿µ °¡À̵å¶óÀÎ:
    https://www.kdca.go.kr/board/board.es?mid=a20507020000&bid=0019&tag=&act=view&list_no=722617
  • (±¹³») Ç×»ýÁ¦ »ç¿ë°ü¸® ÇÁ·Î±×·¥ÀÇ ±¹³» ½ÇÇàÀ» À§ÇÑ Çٽɿä¼Ò -Á¾ÇÕº´¿ø´ë»ó-:
    https://doi.org/10.3904/kjm.2023.98.1.11
  • (±¹³») 2025³â Ç×»ýÁ¦ »ç¿ë·® ºÐ¼® ¹× ȯ·ù½Ã½ºÅÛ ¸Å´º¾ó:
    https://www.konas.or.kr:44538/xe/pds/1974

[ÁÖ¿ä »çÀÌÆ®]

  • ´ëÇѰ¨¿°ÇÐȸ: http://www.ksid.or.kr
  • ´ëÇÑÇ×±Õ¿ä¹ýÇÐȸ: http://www.ksat.or.kr
  • ´ëÇѰáÇÙ ¹× È£Èí±âÇÐȸ: http://www.lungkorea.org
  • Infectious Diseases Society of America (IDSA): http://idsociety.org
  • AIDSinfo: http://aidsinfo.nih.gov/guidelines